SCHEDULE 13G/A: Frazier Life Sciences Group Amends Jade Biosciences Stake

Frazier Life Sciences and affiliated entities filed an amended Schedule 13G, disclosing a collective beneficial ownership of approximately 4.33% in Jade Biosciences, Inc.

Summary

• Frazier Life Sciences Public Fund, L.P. and its general partners (FHMLSP, L.P. and FHMLSP, L.L.C.) collectively report beneficial ownership of 1,384,646 shares of Jade Biosciences, Inc. Common Stock, representing 4.2% of the class.
• This ownership includes shares acquired from Frazier Life Sciences Public Overage Fund, L.P. through a merger.
• Frazier Life Sciences X, L.P. and its general partners (FHMLS X, L.P. and FHMLS X, L.L.C.), along with James N. Topper and Patrick J. Heron, report beneficial ownership of 9,488 shares, representing 0.0% of the class.
• Frazier Life Sciences XI, L.P. and its general partners (FHMLS XI, L.P. and FHMLS XI, L.L.C.) report beneficial ownership of 19,146 shares, representing 0.1% of the class.
• The total beneficial ownership for the entire group of reporting persons is 1,413,280 shares, representing approximately 4.33% of the outstanding Common Stock.
• The percentage of class calculations are based on 32,626,730 shares of Common Stock outstanding as of August 8, 2025.
• The filing certifies that the securities were not acquired or held for the purpose of changing or influencing control of Jade Biosciences, Inc.

Sentiment

Score: 5

Explanation: Neutral. The filing is a routine amendment to a Schedule 13G, disclosing beneficial ownership below the 5% threshold for the primary fund and the overall group. It provides transparency on institutional holdings but does not indicate significant positive or negative developments for the issuer.

Positives

• Continued investment by a specialized life sciences fund group, indicating ongoing interest in Jade Biosciences.
• The filing clarifies the beneficial ownership structure following an internal merger, enhancing transparency.

Negatives

• The reported beneficial ownership by the primary fund (Frazier Life Sciences Public Fund, L.P.) is 4.2%, which is below the 5% threshold typically associated with significant activist or influential stakes, suggesting a passive investment.
• The overall group ownership of 4.33% also remains below the 5% threshold, limiting potential influence.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding Jade Biosciences, Inc. or the reporting persons' future investment intentions beyond the certification that the shares are not held for control purposes.

Industry Context

This filing reflects a routine disclosure by a life sciences-focused investment group, Frazier Life Sciences, regarding its passive stake in Jade Biosciences. Such disclosures are common for institutional investors managing diversified portfolios within specialized sectors like biotechnology or pharmaceuticals. The amendment indicates a change in the structure of their holdings or a slight adjustment in their percentage, which is typical for active funds.

Stakeholder Impact

• Shareholders: Provides transparency regarding the ownership structure of a significant institutional investor group. The passive nature of the investment (below 5% and certified not for control) suggests no immediate impact on corporate control or strategic direction.
• Management: Awareness of institutional ownership, but no direct impact on operations or strategy is implied by this filing.

Key Dates

Recommendation

This Schedule 13G/A filing is a routine disclosure of beneficial ownership by a group of institutional investors. It indicates a passive stake below the 5% threshold, with no stated intent to influence control. As such, it provides no new information that would fundamentally alter the investment thesis for Jade Biosciences, Inc. Investors should continue to hold based on the company's underlying fundamentals and previous disclosures, as this filing does not present a catalyst for a change in recommendation.

Keywords

Jade Biosciences, Frazier Life Sciences, Schedule 13G/A, Beneficial Ownership, Common Stock, SEC Filing, Institutional Investor, Life Sciences Investment, Equity Stake